source
- Cytokinetics reports positive pivotal trial results for aficamten in non-obstructive hypertrophic cardiomyopathyBiotech Cytokinetics disclosed full data from a pivotal study of its drug aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). The trial met both primary endpoints, showin…
- FDA greenlights Takeda and Protagonist's rusfertide (Mimrylo) for polycythemia veraThe U.S. Food and Drug Administration has granted approval to rusfertide, a therapy developed jointly by Takeda Pharmaceutical and Protagonist Therapeutics. The drug, to be marketed under the name…